Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant-Reference-Cited by-同舟云学术

Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant

Published:2022-07-22 Issue:3 Volume:76 Page:e507-e509
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Huygens Sammy¹,Oude Munnink Bas²,Gharbharan Arvind¹,Koopmans Marion²^ORCID,Rijnders Bart¹

Affiliation:

1. Department of Internal Medicine, Section of Infectious Diseases and Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, University Medical Center , Rotterdam , The Netherlands

2. Department of Viroscience, Erasmus Medical Center, University Medical Center , Rotterdam , The Netherlands

Abstract

Abstract Viral evolution was evaluated in 47 immunocompromised patients treated with sotrovimab. Sequencing of SARS-CoV-2 following therapy was successful in 16. Mutations associated with sotrovimab resistance were documented in 6; viral replication continued after 30 days in 5. Combination antibody therapy may be required to avoid acquired resistance in immunocompromised patients.

Funder

European Union’s Horizon 2020, a

ZorgOnderzoek Nederland en het gebied Medische wetenschappen

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac601/45472971/ciac601.pdf

Reference12 articles.

1. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies;VanBlargan;Nat Med,2022

2. Antibody evasion properties of SARS-CoV-2 Omicron sublineages;Iketani;Nature,2022